A A A

piśmiennictwo

1.Barthels M.,Poliwoda H.:Gerinnungsanalysen.Georg Thieme Verlag,Stuttgart 1990,19.
2.Behringwerke AG Informator,Marburg 1990-1996.
3.Belch.J et al.:The white blood cell and plasma fibrinogen in thrombotic stroke.A significant correlation.Int Angiol. 1998 Jun,17(2):120-4.
4.Bio Merieux sa Informator,Marcy-l’Etoile 1990-1996.
5.Boehringer Ingelheim Vademecum,Poznań 1993,3-8.
6.Boysen G.et al.:Alteplase therapy in acute ischemic stroke.A Danish pilot study.Z.Kardiol.1993,82 suppl.2,105-8.
7.Brott T.G.et al.:Urgent therapy for stroke.Part I pilot study of tissue plasminogen activator administered within 90 minutes.Stroke 1992,23(5),632-40.
8.Casto L.et al.:Local intraarterial thrombolysis for acute stroke in the carotid artery territories.Acta Neurol.Scand.1992,86(3),308-11.
9.Catto A.J.,Grant P.J.:Risk factors for cerebrovascular disease and the role of coagulation and fibrinolysis.Blood Coagul.Fibrinolysis 1995,6(6),497-510.
10.Cipolli P.L.et al.:Blood hypercoagulability secondary to experimental cerebral ischemia in the rabbit.Influance of a hyperdyslipidemia induced by an atherogenic diet.Ital.J.Neurol.Sci.1991,12(3),289-93.
11.Cybulska B.,Szostak W.B.:Otyłość wisceralna jako czynnik zagrożenia chorobą niedokrwienną serca. Pol.Tyg.Lek.1995,50 suppl.1,43-47.
12.Członkowska A.:Postępowanie w ostrej fazie udaru niedokrwiennego mózgu-leki specyficzne wpływające na ognisko udarowe.Ter.Leki 1995,XXII/XLIV,1-2,15-21.
13.Członkowska A.:Leki przeciwpłytkowe we wtórnej profilaktyce udaru mózgowego.Post.Psych.Neurol.1995,4,69-74.
14.Ezura M.,Kagawa S.:Selective and supraselective infusion of urokinase for embolic stroke.Surg.Neurol. 1992,38(5),353-8.
15.Ferro D.et al.:Lupus anticoagulant and the fibrinolytic system in young patients with stroke.Stroke 1993, 24(3),368-70.
16.Franceschini G.et al.:Association of lipoprotein(a) with atherothrombotic evants and fibrinolytic variables.Thromb.Res.1995,1,78(3),227-38.
17.de Garba T.J.,La Roy P.:Problemy genetyczne udarów mózgu.Akt.Neurol.1996,1,1,22-27.
18.Glueck C.J.et al.:Hypofibrinolytic and atherogenic risk factors for stroke.J.Lab.Clin.Med.1995,125(3),   319-25.
19.Gryglewski R.:Leki przeciwpłytkowe,II Interdyscyplinarne Forum Udaru Mózgu,Katowice 14.V 1999.
20.Guan K.J.:Changes in the fibrinolytic activity in hypertension and acute cerebral infarction.Chung Hua Hsin Hsueh Kuan Ping Tsa Chih 1993,21(3),150-2,186-7.
21.Gwynn M.:t-PA in acute stroke - risk or reprive.J.Neurosci.Nurs.1993,25(3),180-6.
22.Haley E.C.Jr et al.:Urgent therapy for stroke.Part I pilot study of tissue plasminogen activator administration 91-180 min.from onset.Stroke 1992,23(5),641-5.
23.Haley E.C.Jr et al.:Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke.The t-PA Bridging Study Group.Stroke 1993,24(7),1000-4.
24.Han X.M.et al.:Determination of plasma tissue type plasminogen activator and plasminogen activator inhibitor activity in patients with ischemic stroke.Chung Hua Nei Ko Tsa Chih 1990,29(9),544-6,575-6.
25.Han X.M.:Plasma tissue type plasminogen activator inhibitor activities and their ratio in patients with ischemic stroke associated with stagnation of blood during various stages.Chung Hsi I Chieh Ho Tsa Chih 1991,11(1),17-9,3-4.
26.Hart R.G.,Kanter M.C.:Hematologic disorders and ischemic stroke.A selective review.Stroke 1990,21(8),1111-21.
27.Heinrich J.et al.:Association of variables of coagulation,fibrinolysis and acute phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain.Thromb.Haemost.1995,73(3),374-9.
28.Hernandez-Nunez A.et al.:Alterations of fibrinolysis in stroke.An.Med.Inerna 1996,13(3),107-10.
29.Herderschee D.et al.:Thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke.Evaluation with rCBF-SPECT.Acta Neurol.Scand.1991, 83(5),317-22.
30.Imamura T.et al.:Congenital antithrombin III abnormality and cerebral arterial thrombosis.Stroke 1991,22(8), 1090.
31.Janicki K.:Inhibitory krzepnięcia i fibrynolizy.W: Janicki K.red.:Hematologia kliniczna.PZWL,Warszawa 1991, 1,198-203.
32.Januszewicz W.:Współczesny stan wiedzy na temat inhibitorów konwertazy angiotensyny i ich roli w leczeniu nadciśnienia tętniczego.Kardiol.Pol.1995,XLIVsuppl.I,5-9.
33.Jędrzejowska H.:Niedokrwienny udar mózgu - podział i przyczyny.Post.Psych.Neurol.1995,4(1),41-6.
34.Jovicić A.et al.:Circadian variations of platelet aggregabillity and fibrinolytic activity in patients with ischemic stroke.Thromb.Res.1991,15,64(4),487-91.
35.Kawakami K.et al.:An experimental study of local fibrinolysis using tissue plasminogen activator and urokinase in a canine common carotid artery thrombosis model.No To Shinkei 1990,42(2),193-201.
36.Kazibutowska Z.:Zaburzenia krążenia mózgowego.W:Giec L.,Herman Z.S.red.:Farmakoterapia chorób układu sercowo-naczyniowego.PZWL,Warszawa 1995,3,319-335.
37.Kempter B.et al.:Decreased fibrinolytic stimulation by a short-term venous occlusion test in patients with cerebrovascular diseases.Thromb.Res.1995,15,79(4),363-8.
38.Kinalska J.:Zaburzenia gospodarki lipidowej w cukrzycy.Servier Polska,Diabetografia 1996 wyd.spec.,2-3.
39.Kittelberger R.et al.:An improved immunofluorescence technique for the histological examination of blood vessel tissue.Acta Histochem.Jena 1989,86(2),137-42.
40.Koenig W.:Haemostatic risk factors for cardiovascular diseases.Eur.Heart J.1998,4,19 suppl.C,39-43.
41.Kopeć M.:Fibrynoliza oraz patofizjologia i klinika zakrzepu.W:Janicki K.red.:Hematologia kliniczna,PZWL, Warszawa 1991,1-2,191-216,615-650.
42.Kopieczna-Grzebieniak E.,Wesołowski W.:Lipoproteina(a) i kontrowersyjne poglądy z nią zwiazane.Czynniki ryzyka, PTBNM,Szczecin 1995,3/4(9/10),33-34.
43.Kuczyńska-Zardzewiały A.:Udary mózgu w przebiegu tocznia rumieniowatego układowego i zespołu antyfosfolipidowego.Post.Psych.Neurol.1995,4(1),47-52.
44.von Kummer R.,Hacke W.:Safety and efficiacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke.Stroke 1992,23(5),646 -52.
45.Landin-Wilhelmsen K.:Metformin and blood pressure.J.Clin.Pharm.Ter.1992,17(2),75-9.
46.Lane D.A. et al.:Activation of coagulation and fibrinolytic systems following stroke. Br J Haematol.1983 Apr,53(4):655-8.
47.Lindahl A.K.:Tissue factor pathway inhibitor.Biomed. Progress 1994,3,7,43-6.
48.Lindgren A.et al.:Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients. Stroke 1996,27(6),1066-71.
49.Lottermoser K.et al.:Antihypertensive drug treatment and fibrinolytic function.Am.J.Hypertens.1998,11(3Pt1), 378-84.
50.Maggioni A.P.et al.:The risk of stroke in patients with acute myocardial infarctions after thrombolytic and antithrombotic treatment.N.Engl.J.Med.1992,2,327(1),1-6.
51.Majkowska L.:Otyłość i nadciśnienie tętnicze a zespół insulinooporności.Servier Polska,Diabetografia 1996 wyd. spec.,7-8.
52.Maliński M.,Szymszal J.:Współczesna statystyka matematyczna w medycynie w arkuszach kalkulacyjnych.Ślaska Akademia Medyczna,Katowice,1999.
53.Mammen E.F.:Thrombophilia and hypercoagulability. Biomed. Progress 1993,6,1-2.
54.Mansfield M.W.et al.:Fibrinolytic measurements in type 2 diabetic patients with acute cerebral infarction.Diab. Med. 1998,15(11),953-7.
55.Margaglione M.et al.:Abnormal high circulation levels of tissue plasminogen activator and PAI-1 in patients with a history of ischemic stroke.Arterioscl.Thromb.1994,14 (11),1741-5.
56.Miller T.red.:Elementy statystyki medycznej.PZWL, Warszawa 1976,1.
57.Misz M.et al.:Hemostatic  abnormalities in ischemic stroke.Orv Hetil 1998,18,139(42),2503-7.
58.Monnier L.:Typ otyłości a choroby żył.Servier Polska, Choroby żył a otyłość,1996,5,4-5.
59.Mori.E.et al.:Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992,42(5),976-8.
60.Muller J.E.et al.:Circadian variations and triggers of onset of acute cardiovascular disease.Circulation 1989,79,4,733-43.
61.Nitschkoff S.:Patophysiologie des Herz- Kreislaufsystems.Akademie Verlag,Berlin 1989,82-4.
62.Nowak A.:Udział fibrynolizy w patogenezie śródnaczyniowego odkładania fibryny.Praca habilitacyjna.ŚlAM, Katowice 1975.
63.O’Connor C.M.et al.:Stroke and acute myocardial infarction in the thrombolytic era.Clinical correlates and long-term prognosis.J.Am.Coll.Card.1990,16(3),533-40.
64.Ono N.et al.:Clinical significance of new coagulation and fibrinolysis markers in ischemic stroke patients.Stroke 1991,22(11),1369-73.
65.Ono N.et al.:Influance of atrial fibrillation on coagulo-fibrinolytic markers in patients with cerebral infarction.Int.Angiol.1992,11(4),298-303.
66.Overgaard K.et al.:Thrombolytic therapy in acute ischemic stroke.A Danish pilot study.Stroke 1993,24(10), 1439-46.
67.Pollak V.E.et al.:Ancrod causes rapid thrombolysis in patients with acute stroke.Am.J.Med.Sci.1990,299(5),319-325.
68.Price T.R.:Stroke in patients treated with thrombolytic therapy for acute myocardial infarction.The thrombosis in myocardial infarction clinical trial and a review of placebo controlled trials.Stroke 1990,21 suppl.,3,8-9.
69.Rangemark C.et al.:Platelet function and fibrinolytic activity in hypertensive and normotensive sleep apnea patients.Sleep 1995,18(3),188-94.
70.Reivich M.,Hurtig H.J.:Cerebrovascular diseases.Raven Press,New York 1983.
71.Ryglewicz D.,Członkowska A.:Choroby naczyń mózgowych. Sympozjum szkol.Studium Kształcenia Podyplomowego,CM UJ, Kraków 25.XI 1995.
72.Skotnicki A.B.,Sacha T.:Zaburzenia krzepnięcia krwi. Medycyna Praktyczna,Kraków 1997.
73.Stack S.et al.:Modulation of plasminogen activation and type IV collagenase activity by a synthetic peptide derived from the laminin A chain.Biochemistry 1991,30, 2073-77.
74.Stenzinger W.,Kienast J.:Thrombophilia:how to handle the risk.Biomed.Progress 1993,6,3-6.
75. Stolarzewicz K. i wsp.: Stopniowana neurologiczna i internistyczna skala do stosowania w udarze niedokrwiennym , XIV Zjazd PTN ,Streszczenia,102 ,Warszawa,1990.
76.Szczepański M.:Monitorowanie zaburzeń hemostazy u chorych chirurgicznie.Medycyna 2000,1992,3,25-26,36-40.
77.Tohgi H.et al.:Coagulation-fibrinolysis system in post-stroke patients reciving antiplatelet medication. Stroke 1993,24(6),801-4.
78.Tohgi H.et al.:The anticardiolipin antibody in elderly stroke patients:its effects on stroke types,recurrence and the coagulation-fibrinolysis system.Acta Neurol. Scand.1994,90(2),86-90.
79.Ueda T.et al.:Changes in coagulation and fibrinolysis system after local intra-arterial thrombolysis for acute ischemic stroke.Neurol.Med.Chir.Tokyo 1995,3(3),136-43.
80.Vaitkus P.T.et al.:Stroke complicating acute myocardial infarction.A meta-analysis of risk modification by anticoagulation and thrombolytic therapy.Arch.Intern.Med. 1992,152(10),2020-4.
81.Wechsler B.B.:Zaburzenia hematologiczne a udar niedokrwienny.Aktualności Neurol.1996,1,1,35-41.
82.Wierusz-Wysocka B.,Wysocki H.:Podobienstwa i różnice pomiędzy metabolicznym i kardiologicznym zespołem X. Servier Polska,Diabetografia 1996,wyd.spec.,4-6.
83.Wolpert S.M.et al.:Neuroradiologic evaluation of patients with acute stroke treated with recombinant t-PA. The rt-PA Acute Stroke Study Group.Am.J.Neuroradiol.1993, 14(1),3-13.
84.Zawilska K.:Postępy w diagnostyce wewnątrznaczyniowej aktywacji fibrynolizy.Acta Haematol.Polonica 1995,26,1,33 -38.
85.Zawilska K.:Leki fibrynolityczne - praktyczne zastosowanie osiągnięć biologii molekularnej.Terapia 1996,2,3-7.
86.Zeumer H.et al.:Local intra-arterial fibrinolytic therapy in patients with stroke.Urokinase versus recombinant tissue plasminogen activator rt-PA.Neuroradiology 1993,35 (2),159-62.
87.del Zoppo G.J.:An open multicenter trial of recombinant tissue plasminogen activator in acute stroke.Stroke 1990,21(12 suppl.),4,174-5.
88.del Zoppo G.J.et al.:Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke.Ann.Neurol.1992,32(1),78-86.
89.del Zoppo G.J.,Pessin M.S.,Mori E.:Thrombotic intervention in acute thrombotic and embolic stroke.Z.Kardiol.1993,82 suppl.2,89-104.